Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now?

Is IDYA a bully banal to buy? We came crossed a bullish thesis on IDEAYA Biosciences, Inc. connected Valueinvestorsclub.com by pestopenguin. In this article, we volition summarize the bulls’ thesis connected IDYA. IDEAYA Biosciences, Inc.'s stock was trading astatine $29.48 arsenic of April 27^th. IDYA’s guardant P/E was 4.65 according to Yahoo Finance.

Tonhom1009/Shutterstock.com

Ideaya Biosciences is positioned arsenic a catalyst-rich precision oncology institution arsenic investors absorption connected the upcoming Phase II–III OptimUM-02 readout for darovasertib successful first-line HLA-A2-negative metastatic uveal melanoma successful 1Q 2026, which represents a pivotal de-risking lawsuit for its pb program.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

Darovasertib, a PKC inhibitor partnered with crizotinib, targets GNAQ/GNA11-driven signaling done dual MAPK and c-MET pathway suppression, and anterior Phase 1–2 OptimUM-01 information demonstrated astir 7-month median progression-free endurance and 21-month wide endurance with a favorable information illustration versus modular therapies.

Importantly, the pivotal survey compares against investigator’s prime therapies wherever humanities progression-free endurance is astir 3 months, meaning a humble ~5.5-month threshold could beryllium capable for statistical success, portion competitory benchmark Kimmtrak reinforces the commercialized validity of the indication.

With implicit 90% of patients harboring GNAQ oregon GNA11 mutations, the first-line HLA-A2-negative metastatic uveal melanoma marketplace represents astir $300 cardinal successful near-term gross imaginable and expands toward a broader $1.6 cardinal accidental crossed attraction lines, further supported by orphan and breakthrough designations that fortify regulatory visibility.

Ideaya maintains a beardown equilibrium expanse with astir $1.1 cardinal successful currency providing runway into 2030, supplemented by a $210 cardinal upfront Servier concern with further milestones and cost-sharing, importantly reducing near-term dilution risk.

Overall, the upcoming readout represents a high-probability catalyst to validate darovasertib’s mechanism, perchance supporting accelerated support and meaningful rerating of Ideaya Biosciences, with base-case scenarios implying beardown upside and favorable risk-reward skew versus existent marketplace expectations and constricted downside fixed de-risked objective illustration and improving sentiment expected ahead.

Previously, we covered a bullish thesis connected Moderna, Inc. (MRNA) by YouAlwaysHaveAChoice successful February 2025, which highlighted infectious illness catalysts, organization accumulation, and method bullish signals. MRNA's banal terms has appreciated by astir 46.33% since our coverage. pestopenguin shares a akin presumption but emphasizes Ideaya Biosciences’ upcoming objective catalyst, beardown equilibrium sheet, and de-risked oncology pipeline driving asymmetric upside successful biotech.